Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low - Time to Sell?

Arcus Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Arcus Biosciences hit a new 52-week low, trading as low as $15.69. Its shares are well below the 50-day and 200-day moving averages of $21.85 and $24.36, respectively.
  • Analyst sentiment remains broadly positive: 12 analysts rate the stock Buy, three Hold, and one Sell, for a “Moderate Buy” average rating and a $39.36 average price target.
  • The latest quarter showed mixed results: Arcus reported an $1.00-per-share loss, worse than the $0.89 consensus estimate, while revenue of $9 million exceeded forecasts but fell 65.4% year over year.
  • Five stocks to consider instead of Arcus Biosciences.

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $15.69 and last traded at $15.96, with a volume of 55,190 shares trading hands. The stock had previously closed at $15.76.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RCUS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Thursday, October 15th. The Goldman Sachs Group reissued a "buy" rating and issued a $42.00 price objective on shares of Arcus Biosciences in a research report on Friday, August 7th. Wedbush reduced their price objective on shares of Arcus Biosciences from $49.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, November 5th. Wells Fargo & Company raised their target price on shares of Arcus Biosciences from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a research report on Monday, August 10th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences has an average rating of "Moderate Buy" and an average target price of $39.36.

Check Out Our Latest Stock Report on Arcus Biosciences

Arcus Biosciences Price Performance

The company has a 50 day moving average of $21.85 and a 200 day moving average of $24.36. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -4.36 and a beta of 1.04. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.28.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.11). The business had revenue of $9.00 million during the quarter, compared to analyst estimates of $7.58 million. Arcus Biosciences had a negative return on equity of 91.65% and a negative net margin of 453.00%. The firm's quarterly revenue was down 65.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.27) earnings per share. As a group, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.49 EPS for the current fiscal year.

Insider Activity at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Arcus Biosciences during the second quarter worth approximately $506,113,000. Goldman Sachs Group Inc. boosted its holdings in shares of Arcus Biosciences by 18.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,637,095 shares of the company's stock valued at $42,286,000 after purchasing an additional 249,529 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $28,341,000. Aberdeen Group plc grew its stake in shares of Arcus Biosciences by 62.4% during the 3rd quarter. Aberdeen Group plc now owns 1,056,679 shares of the company's stock valued at $27,294,000 after buying an additional 405,967 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $25,759,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus's research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines